The DO-HEALTH trial will be extended into the cohort including the collection on life style factors such as diet, quality of life and physical activity, as well as health-related data on co-morbid conditions as well as a standardized assessment of multiple organ functions, physical, cognitive and mental function using surveys and standardized health assessments.
The DO-HEALTH cohort will be a continuation of the trial without intervention and will elucidate longterm determinants of healthy, active and independent aging in European community-dwelling older adults. The main emphasize of the cohort will be to determine the risk factors, to quantify the incidence and to describe the trajectories of incident frailty, impaired mobility, loss of independence and age related morbidity (e.g. heart arrhythmia, type 2 diabetes, falls, fractures). Additionally, the cohort will continue to investigate the primary endpoints of the original trial like the risk and incidence of injurious falls (bone); functional decline (muscle); high blood pressure (cardiovascular); cognitive decline (brain); and the rate of any infection (immunity). Moreover, the cohort will include and extend key secondary and exploratory endpoints of the original trial such as incidence and prevalence of anemia, sarcopenia, cardiovascular diseases, type 2 diabetes and cancer.
Study Type
OBSERVATIONAL
Enrollment
534
Centre on Aging and Mobility, University of Zurich, City Hospital Zurich
Zurich, Switzerland
Incidence of functional decline
assessed by short physical performance test battery
Time frame: 24 months
Incidence of injurious falls
assessed by fall questionnaire at each visit
Time frame: 24 months
Incidence of high blood pressure
Standardized blood pressure assessment in sitting position
Time frame: 24 months
Incidence of cognitive decline
assessed by Montreal Cognitive Assessment (MoCA)
Time frame: 24 months
Incidence of infections
assessed by infection questionnaire at each visit
Time frame: 24 months
Incidence and prevalence of frailty
based on criteria by L. Fried (shrinking, weakness, poor endurance and energy, slowness, low physical activity level), SHARE-FI
Time frame: 24 months
Incidence and prevalence of impaired mobility
assessed by EQ5D-3L, physical activity questionnaire
Time frame: 24 months
Incidence and prevalence of functional dependency
assessed by PROMIS-HAQ
Time frame: 24 months
Incidence and prevalence of anemia or iron deficiency
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
assessed by blood markers (ferritin, soluble transferrin receptor, RBC, Hb, erythrocyte indices (MCV, MCH, MCHC), reticulocytes)
Time frame: 24 months
Incidence and prevalence of any cardiovascular disease
assessed by medical history
Time frame: 24 months
Incidence and prevalence of heart arrhythmia
assessed by ECG
Time frame: 24 months
Incidence and prevalence of atrial fibrillation
assessed by ECG
Time frame: 24 months
Incidence and prevalence of heart failure, cardiomyopathy, heart valves abnormalities
assessed by medical history, ECG, physical examination
Time frame: 24 months
Incidence of stroke
assessed by medical history
Time frame: 24 months
Incidence and prevalence of Type 2 diabetes
assessed by medical history
Time frame: 24 months
Incidence and prevalence of dementia
assessed by medical history
Time frame: 24 months
Incidence and prevalence of osteoarthritis
assessed by medical history
Time frame: 24 months
Incidence and prevalence osteoporosis
assessed by medical history
Time frame: 24 months
Incidence and prevalence of sarcopenia, osteosarcopenia
assessed by medical history
Time frame: 24 months
Incidence and prevalence of any gastrointestinal disease
assessed by medical history
Time frame: 24 months
Incidence and prevalence of gastroesophageal reflux disease (GERD)
assessed by medical history
Time frame: 24 months
Incidence and prevalence of any micronutrient deficiency (Vitamins, Minerals and fatty acids)
assessed by medical history
Time frame: 24 months
Incidence and prevalence of knee buckling
assessed by medical history, Buckling, KOOS, HOOS
Time frame: 24 months
Incidence and prevalence of chronic pain
assessed by medical history, McGill, Joint Map, EQ5D-3L
Time frame: 24 months
Incidence and prevalence of subjective memory complaints
assessed by medical history, MoCA, MACQ
Time frame: 24 months
Incidence and prevalence of hearing impairment
assessed by medical history, hearing test, physical examination
Time frame: 24 months
Incidence and prevalence of depression
assessed by medical history, GDS
Time frame: 24 months
Incidence and prevalence insomnia
assessed by medical history, Insomnia
Time frame: 24 months
Incidence and prevalence of chronic inflammation
assessed by medical history, blood marker (e.g. CRP)
Time frame: 24 months
Incidence and prevalence of polypharmacy
assessed by medication
Time frame: 24 months
Incidence and prevalence of inappropriate medication prescription
assessed by medication
Time frame: 24 months
Incidence and prevalence of age related morbidity by individual drug use (e.g. Proton-Pump-Inhibitors, anticoagulants, benzodiazepines, antibiotics)
assessed by medication
Time frame: 24 months
Incidence and prevalence of malnutrition
assessed by medical history, FFQ, GOHAI, Rome
Time frame: 24 months
Incidence and prevalence of urinary incontinence
assessed by medical history, IPPS, QUID
Time frame: 24 months
Incidence and prevalence of impaired quality of life
assessed by EQ5D-3L
Time frame: 24 months
Incidence and prevalence of functional decline
assessed by medical history
Time frame: 24 months
Incidence of fractures
assessed by fracture rate
Time frame: 24 months
Incidence of all-cause hospitalization
assessed by medical history
Time frame: 24 months
Incidence and prevalence of frequent health care utilization
assessed by medical history
Time frame: 24 months
trajectories of frequent health care utilization
assessed by medical history
Time frame: 24 months
Incidence of nursing home placement
assessed by medical history
Time frame: 24 months
Incidence of cancer (any cancer, gastro-intestinal, breast cancer in women, prostate cancer in men)
assessed by medical history
Time frame: 24 months
Incidence of all-cause mortality
Time frame: 24 months
Prevalence of MIND diet adherence (DO-HEALTHcohort-MINDful substudy)
assessed by FFQ
Time frame: 24months
Prevalence and Incidence of Mild Cognitive impairment (DO-HEALTHcohort-MINDful substudy)
assessed by MoCA
Time frame: 24months
Dual-tasking gait variability (DO-HEALTHcohort-MINDful substudy)
assessed by GAITRite® Platinum (Basel only)
Time frame: one time
Prevalence of confirmed Covid-19 cases (DO-HEALTHcohort-MINDful substudy)
assessed by medical history
Time frame: 24 months
Prevalence of Covid-19 vaccinated participants (DO-HEALTHcohort-MINDful substudy)
assessed by medical history
Time frame: 24 months
Prevalence of reported subjective cognitive decline (DO-HEALTHcohort-MINDful substudy)
assessed by MAC-Q, GDS, EQ5D-3L
Time frame: 24 months
Covid-19 related resilience (DO-HEALTHcohort-MINDful substudy)
assessed by Brief Resilience Scale (BRS)
Time frame: one time
Covid-19 related stress (DO-HEALTHcohort-MINDful)
assessed by Covid-19 Pandemic Stress Scale (CPSS)
Time frame: one time
Covid-19 related coping behaviours (DO-HEALTHcohort-MINDful)
assessed by Pandemic Coping Scale (PCS)
Time frame: one time